Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.

Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB.

Clin Cancer Res. 2019 Jul 15;25(14):4211-4223. doi: 10.1158/1078-0432.CCR-18-0871. Epub 2019 Feb 27. Review.

PMID:
30814108
2.

Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.

Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R; Head and Neck Cancer Disease Site Group.

Curr Oncol. 2010 Jun;17(3):37-48.

3.

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Taberna M, Oliva M, Mesía R.

Front Oncol. 2019 May 20;9:383. doi: 10.3389/fonc.2019.00383. eCollection 2019. Review.

4.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL.

J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.

5.

Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy.

Canning M, Guo G, Yu M, Myint C, Groves MW, Byrd JK, Cui Y.

Front Cell Dev Biol. 2019 Apr 9;7:52. doi: 10.3389/fcell.2019.00052. eCollection 2019. Review.

6.

Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.

Solomon B, Young RJ, Rischin D.

Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240. doi: 10.1016/j.semcancer.2018.01.008. Epub 2018 Jan 31. Review.

PMID:
29355614
7.

Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.

Łasińska I, Kolenda T, Teresiak A, Lamperska KM, Galus Ł, Mackiewicz J.

Anticancer Agents Med Chem. 2019;19(3):290-303. doi: 10.2174/1871520618666180910092356.

PMID:
30198439
8.

TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.

Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N.

Cancer. 2017 May 15;123(10):1778-1790. doi: 10.1002/cncr.30570. Epub 2017 Mar 13.

9.

Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.

Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P.

Cancer Treat Rev. 2018 Apr;65:78-86. doi: 10.1016/j.ctrv.2018.03.003. Epub 2018 Mar 20. Review.

PMID:
29574334
10.

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC.

Lin W, Chen M, Hong L, Zhao H, Chen Q.

Front Oncol. 2018 Nov 21;8:532. doi: 10.3389/fonc.2018.00532. eCollection 2018. Review.

11.

Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Sacco AG, Cohen EE.

J Clin Oncol. 2015 Oct 10;33(29):3305-13. doi: 10.1200/JCO.2015.62.0963. Epub 2015 Sep 8. Review.

PMID:
26351341
12.

Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Gildener-Leapman N, Ferris RL, Bauman JE.

Oral Oncol. 2013 Dec;49(12):1089-96. doi: 10.1016/j.oraloncology.2013.09.009. Epub 2013 Oct 11. Review.

13.

Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.

Rothschild U, Muller L, Lechner A, Schlösser HA, Beutner D, Läubli H, Zippelius A, Rothschild SI.

Swiss Med Wkly. 2018 May 14;148:w14625. doi: 10.4414/smw.2018.14625. eCollection 2018. Review.

14.

Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).

Azoury SC, Gilmore RC, Shukla V.

Discov Med. 2016 Jun;21(118):507-16. Review.

15.

Checkpoint immunotherapy in head and neck cancers.

Zolkind P, Uppaluri R.

Cancer Metastasis Rev. 2017 Sep;36(3):475-489. doi: 10.1007/s10555-017-9694-9. Review.

PMID:
28836124
16.

An update: emerging drugs to treat squamous cell carcinomas of the head and neck.

Lee YS, Johnson DE, Grandis JR.

Expert Opin Emerg Drugs. 2018 Dec;23(4):283-299. doi: 10.1080/14728214.2018.1543400. Epub 2018 Nov 16.

PMID:
30376740
18.

Clinical immunotherapeutic approaches for the treatment of head and neck cancer.

Kareemaghay S, Tavassoli M.

Int J Oral Maxillofac Surg. 2019 Apr;48(4):419-436. doi: 10.1016/j.ijom.2018.10.012. Epub 2018 Nov 3. Review.

PMID:
30401512
19.

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.

Larkins E, Blumenthal GM, Yuan W, He K, Sridhara R, Subramaniam S, Zhao H, Liu C, Yu J, Goldberg KB, McKee AE, Keegan P, Pazdur R.

Oncologist. 2017 Jul;22(7):873-878. doi: 10.1634/theoncologist.2016-0496. Epub 2017 May 22.

20.

Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Jacob LA, Chaudhuri T, Lakshmaiah KC, Babu KG, Dasappa L, Babu M, Rudresha AH, Lokesh KN, Rajeev LK.

Indian J Cancer. 2016 Oct-Dec;53(4):471-477. doi: 10.4103/0019-509X.204786. Review.

Supplemental Content

Support Center